



# McGill

Faculty of  
Medicine and  
Health Sciences

Faculté de  
médecine et des  
sciences de la santé

## Gerald Bronfman Department of Oncology



# ONCO 645

## Seminars in Global Oncology

(Winter 2023 Session)

Open to all graduate students enrolled in the  
Faculty of Medicine and Health Sciences  
(required course for the graduate diploma in oncology)

### Course Coordinators:

Eduardo L. Franco, O.C., MPH, DrPH, PhD (Hon), FRSC, FCAHS

[eduardo.franco@mcgill.ca](mailto:eduardo.franco@mcgill.ca), Phone: 514-398-6032

Argerie Tsimicalis, RN, PhD

[argerie.tsimicalis@mcgill.ca](mailto:argerie.tsimicalis@mcgill.ca), Phone: 514-770-6069

**Course Description:** Through a series of interactive lectures and student debates/presentations the course will allow students to identify challenges and strategies for addressing the entire spectrum of cancer prevention and control activities, including diagnosis and access to therapy and end-of-life care, health economics, as well as cancer research and education from an international partnership perspective.

**Language of Instruction:** English is the language of instruction, but in accord with McGill University's Charter of Students' Rights, students in this course have the right to submit in English or French any written work that is to be graded. Conformément à la Charte des droits de l'étudiant de l'Université McGill, chaque étudiant a le droit de soumettre en français ou en anglais tout travail écrit devant être noté.

**Learning Outcomes:** By the end of this course students should have gained a better understanding of (i) the global variation and disparities in cancer prevention, diagnosis, and care; (ii) the health economics of cancer control from an equity lens perspective; and (iii) the opportunities for capacity building, research collaborations, knowledge sharing, policymaking, and for influencing global cancer control and care.

**Term:** Winter 2023: January 12 to April 13 (Thursdays, 2 to 5 PM EST)

Course pre-requisite(s): None

Course co-requisite(s): None

**Number of Credits:** 3

**Course Location:** Given the wide geographical diversity for some speakers and students, the course will be taught mostly via Zoom (McGill myCourses platform). Tutoring and group discussions may be held in person at Room 740, 5100 de Maisonneuve Blvd West (the Department of Oncology's HQ). All session times refer to Eastern North America Standard Time.

**Assessment:**

- Assiduity and in-class engagement: 15%
- Mid-term exam: 25%
- Student debate: 30%
- Final exam: 30%

**Academic Integrity:** McGill University values academic integrity. Therefore, all students must understand the meaning and consequences of cheating, plagiarism and other academic offenses under the Code of Student Conduct and Disciplinary Procedures" (see [www.mcgill.ca/students/srr/honest/](http://www.mcgill.ca/students/srr/honest/) for more information).

**Copyright:** ©Instructor-generated course materials (e.g., handouts, notes, summaries, exam questions, etc.) are protected by law and may not be copied or distributed in any form or in any medium without the explicit permission of the instructor. Note that infringements of copyright can be subject to follow up by the University under the Code of Student Conduct and Disciplinary Procedures.

**Course Content:** In the event of extraordinary circumstances beyond the University's control, the content and/or evaluation scheme in this course is subject to change.

## Course Agenda: Schedule of Lectures and Activities

Day	Session	Time (PM)	Lecturer	Lecture or Content
12-Jan	1	2:00 - 3:25	Eduardo Franco & Argerie Tsimicalis	Introduction to the course
	2	3:35 - 5:00	Eduardo Franco	International variation, time trends, and social determinants of cancer incidence and mortality (I)
19-Jan	3	2:00 - 3:25	Timothy Evans	Global Health and Oncology: Matching Resources with Needs
	4	3:35 - 5:00	Prabhat Jha	Death and Taxes: Hazards of smoking and the benefits of taxation and cessation of cigarettes
26-Jan	5	2:00 - 3:25	Eduardo Franco	International variation, time trends, and social determinants of cancer incidence and mortality (II)
	6	3:35 - 5:00	Gary Rodin	Global Access to Palliative Care: Challenges and Solutions in High and Low Resource Settings
02-Feb	7	2:00 - 3:25	Gina Ogilvie	Designing cancer screening trials in low- and middle-income country settings
	8	3:35 - 5:00	Michael Pollak	Global trends in obesity and cancer: insights, fallacies, and challenges
09-Feb	9	2:00 - 3:25	Argerie Tsimicalis	Costs of Childhood Cancer: Importance of international collaborations among patient organizations and healthcare teams
	10	3:35 - 5:00	Melissa Henry	Psychosocial and Survivorship Support from an International Perspective
16-Feb	11	2:00 - 3:25	Rifat Atun	Expanding global access to cancer care and control: an investment imperative
	12	3:35 - 5:00	Ananya Banerjee	Pursuit of health equity in global oncology
23-Feb	13	2:00 - 3:25	Isabel dos Santos Silva	Global disparities in access to cancer care
	14	3:35 - 5:00	Satish Gopal	Evolving and prioritizing global health at the U.S. National Cancer Institute
02-Mar	No class (reading week)			
09-Mar	15	2:00 - 3:25	Benjamin Anderson	Improving global breast cancer outcomes through health systems strengthening: WHO's Global Breast Cancer Initiative
	16	3:35 - 5:00	Eduardo Franco & Argerie Tsimicalis	Content review, midterm exam
16-Mar	17	2:00 - 3:25	Cary Adams	Influencing the Global Health Agenda - a Cancer Perspective
	18	3:35 - 5:00	Eduardo Franco & Argerie Tsimicalis	Student debates
23-Mar	19	2:00 - 3:25	Christopher Booth	The value crisis in global cancer care

	<b>20</b>	3:35 - 5:00	Ophira Ginsburg	Women, power, and the cancer divide: A Lancet Commission update
30-Mar	<b>21</b>	2:00 - 3:25	Ipshita Prakash	international variation of practices in prevention, diagnosis, and treatment of breast cancer
	<b>22</b>	3:35 - 5:00	Eduardo Franco & Argerie Tsimicalis	Student debates
06-Apr	<b>23</b>	2:00 - 3:25	Elisabete Weiderpass	IARC's mission: cancer research for cancer prevention. Perspectives from the IARC Director
	<b>24</b>	3:35 - 5:00	Eduardo Franco & Argerie Tsimicalis	Student debates
13-Apr	<b>25</b>	2:00 - 3:25	Danielle Rodin & Meredith Giuliani	Advancing Global Cancer Control through Academic Medical Centres
	<b>26</b>	3:35 - 5:00	Eduardo Franco & Argerie Tsimicalis	Content review, final exam

Times are Eastern Standard Time (North America). Daylight Saving Time begins on March 12 in North America.

TO REACH THE INSTRUCTOR:

**Email:** [eduardo.franco@mcgill.ca](mailto:eduardo.franco@mcgill.ca)

**Office phone:** 514-398-6032

**Zoom calls:** <https://mcgill.zoom.us/my/eduardo.franco>

**Cell phone:** 514-975-3237 (quick consultations by text message, WhatsApp, and voice)

**Speakers' Biographies (mostly chronological order as per the course agenda)****Timothy G. Evans, MD, DPhil**

Dr Evans joined McGill University in September 2019 as the Inaugural Director and Associate Dean of the School of Population and Global Health (SPGH) in the Faculty of Medicine and Associate Vice-Principal (Global Policy and Innovation). He joined McGill after a 6-year tenure as the Senior Director of the Health, Nutrition and Population Global Practice at the World Bank Group. From 2010 to 2013, Dr. Evans was Dean of the James P. Grant School of Public Health at BRAC University in Dhaka, Bangladesh, and Senior Advisor to the BRAC Health Program. From 2003 to 2010, he was Assistant Director General at the World Health Organization (WHO). Prior to this, he served as Director of the Health Equity Theme at the Rockefeller Foundation. Earlier in his career he was an attending physician of internal medicine at Brigham and Women's Hospital in Boston and was an Assistant Professor in International Health Economics at the Harvard School of Public Health. Dr. Evans has been at the forefront of advancing global health

equity and strengthening health systems delivery for more than 20 years. At WHO, he led the Commission on Social Determinants of Health and oversaw the production of the annual World Health Report. He has been a co-founder of many partnerships, including the Global Alliance on Vaccines and Immunization (GAVI), as well as efforts to increase access to HIV treatment for mothers and innovative approaches to training community-based midwives in Bangladesh. Dr. Evans received his medical degree from McMaster University in Canada and was a Research and Internal Medicine Resident at Brigham and Women's Hospital. He earned a DPhil in Agricultural Economics from the University of Oxford, where he was a Rhodes Scholar.

**Prabhat Jha, O.C., MD, DPhil, FCAHS, FRSC**

Professor Prabhat Jha is a University Professor at the University of Toronto, Endowed Professor in Global Health and Epidemiology and Canada Research Chair at the Dalla Lana School of Public Health, and the founding Director of the Centre for Global Health Research at St. Michael's Hospital. Professor Jha is the lead investigator of the Million Death Study in India, which quantifies the causes of premature mortality in over 3 million homes from 1998 to current. His publications on tobacco control have enabled a global treaty now signed by over 180 countries. He founded the Statistical Alliance for Vital Events, which focuses on reliable measurement of premature mortality worldwide. Earlier, Professor Jha served in senior roles at the World Health Organization and the World Bank. He was made an

Officer of the Order of Canada in 2012. Professor Jha holds an M.D. from the University of Manitoba and a D.Phil. from Oxford University, where he studied as a Rhodes Scholar.





### **Gary Rodin, MD, FRCPC**

Dr Rodin is a Professor of Psychiatry and Director of the Global Institute of Psychosocial, Palliative and End-of-Life Care (GIPPEC) at the University of Toronto. He is Senior Scientist, Princess Margaret Cancer Centre. He is the inaugural Director of the Cancer Experience Program , a comprehensive program at the Princess Margaret Cancer Centre to support the interconnected well-being of patients with cancer and their families, staff, and trainees. Dr. Rodin is a Senior Scientist and leads an internationally recognized clinical and research program at the Princess Margaret Cancer Centre. This research is focused on the development, evaluation, and global implementation of novel interventions to improve the psychological wellbeing and quality of life of patients with cancer and their families. He has also been engaged in global research and advocacy to improve the quality of care in the last year of life and the quality of dying and death. Dr. Rodin has published widely in these areas and has been recognized for his global efforts to ensure universal access to

psychosocial and palliative interventions and optimal end-of-life care for patients and families facing advanced disease.



### **Gina Ogilvie, MD, MSc, DrPH, FCFP**

Professor Ogilvie is a Tier 1 Canada Research Chair in Global Control of HPV related diseases and prevention, and Professor at the University of British Columbia in the School of Population and Public Health. She is also Senior Public Health Scientist at BC Centre for Disease Control and Senior Research Advisor at the BC Women's Hospital and Health Centre. She was previously Medical Director of Clinical Prevention Services at BC Centre for Disease Control where she provided both operational and scientific leadership to an integrated public health unit with over 100 staff. This unit focuses on providing public health leadership and service in STIs, HIV, Hepatitis and Tuberculosis provincially, nationally, and globally. Her research is focused on both the public health and clinical aspects of reproductive health, sexually transmitted infections, HPV screening and the HPV vaccine, and her findings have been highly influential in setting and directing health policy both in Canada and globally. Among other research projects, she is principal investigator for the ASPIRE program, a global health initiative conducting research and providing women-centred, innovative solutions for cervical cancer prevention and

reproductive health in sub-Saharan Africa. She received numerous awards, including UBC Killam Research Prize (2021); American Sexually Transmitted Diseases Association Achievement Award (2020); Michael S. O'Malley Alumni Award for Publication Excellence (2019); YWCA Woman of Distinction (2018); President's Award, Children and women's Health Centre of BC (2018); Options for Sexual health Sexual Health Champion of the Year (2018); Provincial Health Officer's Award for Excellence in Public health (2015); Researcher of the Year, College of Family Physicians of Canada (2014); YWCA Women of Distinction Nominee (2014); Distinguished Achievement in Research, Faculty of Medicine, University of British Columbia (2014). In 2019, she was part of the Governor General's Official Delegation to the 25th Commemoration of the Rwandan Genocide.

**Michael Pollak, MD, FRCPC, FRSC**

Dr Pollak is a tenured Professor in the Department of Oncology at McGill University in Montreal and holds the Alexander-Goldfarb Research Chair. His medical education was at McGill, and post-graduate specialist training in Oncology was at the University of Toronto. He practices medical oncology at the Jewish General Hospital. His research focuses on the intersection of oncology, endocrinology, and metabolism and he employs a multidisciplinary approach, using both laboratory and population methods. He heads the Division of Cancer Prevention at the Department of Oncology at McGill and the Stroll Cancer Prevention Centre at the Jewish General Hospital. He collaborates widely with researchers around the world. In 2012, he was awarded the Aisenstadt Award for Academic Achievement by McGill/JGH faculty and the Harold Warwick Prize by the Canadian Cancer Society Research Institute. He is co-Editor-in-Chief, *Cancer Prevention Research* a journal published by the American Association for Cancer Research. He is also co-Editor-in-Chief of *Cancer Metabolism*, a Springer-Nature journal.

**Melissa Henry MPs, PhD**

Dr. Henry is an Associate Professor at McGill University in the Department of Oncology, as well as an Associate Member in the Department of Otolaryngology – Head and Neck Surgery. She is an investigator at the Lady-Davis Institute for Medical Research and a psychologist at the Segal Cancer Centre of the Jewish General Hospital. She actively collaborates with colleagues nationally and internationally via her research program that aims to implement and evaluate interventions targeting early determinants of mental health, combining translational research with a major focus on advanced cancer and head and neck oncology. Her research program in head and neck oncology is contributing to our better understanding of the biological component to biopsychosocial vulnerability, including the underlying contribution of polygenic risk scores, gene-environment interactions, and immunological processes. She has developed the FACT/MBIS McGill Body Image Concern Scale – Head and Neck. Dr. Henry is Co-Director of the FRQS-funded Quebec Research Group in Palliative and End-of-Life Care (RQSPAL) Axis I on optimizing quality of life in palliative and end-of-life care. She is a board member of

the International Psycho-Oncology Society (IPOS) and as such is involved in building and Chairing Training Academies in Africa and more broadly for low-middle-income countries. Her international work involves advocating for comprehensive cancer care, and work with IPOS and the World Health Organization towards implementing psycho-oncology in National Cancer Plans and as part of Universal Health initiatives worldwide.

**Rifat Atun, MD, MBA, FRCGP, FRCP(UK)**

Dr Atun is Professor of Global Health Systems at Harvard University and the Chair for the Harvard Ministerial Leadership Program. In 2006-13, Dr Atun was Professor of International Health Management and Head of the Health Management Group at Imperial College London. In 2008-12 he served as a member of the Executive Management Team of The Global Fund to Fight AIDS, Tuberculosis and Malaria as the Director of Strategy, Performance and Evaluation Cluster, where he chaired the panel that oversaw investments of around \$4billion each year in more than 100 countries. His research has two major strands. The first examines health systems performance and how design and implementation of health system reforms impact on outcomes. The second explores adoption of innovations in health systems (e.g. new health technologies, disease control programmes, and primary healthcare reforms), and innovative financing in global health. Prof. Atun is a co-Investigator and the joint lead for the innovation work stream at the National Centre for Infection

Prevention and Management at Imperial College. He is also a co-Investigator and the Theme Lead for 'Organisational Change, Health Economics and Evaluation' at the NIHR Health Protection Research Unit for Antimicrobial Resistance and Healthcare Associated Infection. Prof. Atun has worked with more than 30 governments globally and with the World Bank, World Health Organization, and the UK Department for International Development (DfID) to design, implement and evaluate health system reform initiatives. In 1999-2006 he was a member of the UK DfID Resource Centre for Health Systems. Prof. Atun was the Founding Director of the MSc in International Health Management, BSc in Management and Medical Science, and Founding Co-Director of the MPH Programmes at Imperial College.

**Ananya Tina Banerjee, PhD**

Dr. Banerjee is Assistant Professor at the Department of Epidemiology, Biostatistics and Occupation Health, McGill University and member of SHERPA University Institute. Her interdisciplinary epidemiologic and qualitative research embeds a strong emphasis on community-based participatory pedagogy and research, which is grounded in collaboration and partnership with racialized communities. Often, the research questions she pursues are community-defined problems in the context of health equity and intersectionality funded by the Canadian Institute of Health Research, Social Science & Humanities Research Council and Public Health Agency of Canada. She developed and offered the first course on race and health in a school of public health in Canada. She is well known for her anti-racism and anti-oppression practice in the learning

environment and providing critical mentorship for racialized students in public health programs. She won the 2022 Teaching Innovation Award of McGill's Faculty of Medicine and Health Sciences recognizing her unique pedagogy for inclusive public health education and serves on The Lancet's International Advisory Board for Racial Inequalities. Dr. Banerjee has been prominent advocate in the media pushing for vaccine equity in Canada and globally during the COVID-19 pandemic.



**Isabel dos Santos Silva, MD, MSc, PhD**

Dr Santos Silva is a Professor of Epidemiology in the Department of Epidemiology of Non-Communicable Diseases at the London School of Hygiene and Tropical Medicine (LSHTM), University of London. She completed her medical degree at the Universidade Clássica de Lisboa, Portugal, before moving to the England to complete an MSc in Medical Demography followed by a PhD in cancer epidemiology. Her research has focused on cancer epidemiology and control in high-income as well as low-/middle-income countries, with a particular emphasis on sub-Saharan Africa, Latin America and, more recently, China. She is a Senior Visiting Scientist at the International Agency for Research on Cancer (IARC), and a principal investigator of the US National Cancer Institute-funded African Breast Cancer – Disparities in Outcomes (ABC-DO) study (jointly with Dr. Valerie McCormack from IARC), which is being conducted in six sub-Saharan countries to investigate the drivers of the poor survival in the

region from this potentially curable cancer. She has published widely in peer-reviewed journals and has authored several books including the IARC/WHO textbook “Cancer Epidemiology: Principles and Methods”. She was also an Associated Editor of the last (sixth) edition of the classic “A Dictionary of Epidemiology” sponsored by the International Epidemiological Association (IEA). She has successfully supervised many MSc and PhD students over the years and has taught on many short courses overseas including in Africa, Asia and Latin America.

**Satish Gopal, MD, MPH**

Dr Gopal was appointed Director of the Center for Global Health (CGH) at the National Cancer Institute (NCI) in February 2020. In this role, he oversees the development of initiatives and collaborations with other NCI divisions, NCI-Designated Cancer Centers, and countries to support cancer research and cancer research networks, promote cancer control planning, and build capacity in low- and middle-income countries. In 2018 he was selected to advise the NCI Director on the NCI global portfolio as Co-Chair of the NCI Advisory Board Ad Hoc Global Health Working Group. Before coming to NCI, Dr. Gopal was the Cancer Program Director for the University of North Carolina (UNC) Project-Malawi, in collaboration with the Malawi Ministry of Health. Dr. Gopal completed his Master of Public Health in 2000 at UNC-Chapel Hill and earned his medical degree from the Duke University School of Medicine in 2001. He was trained in internal medicine and pediatrics at

the University of Michigan, lived and worked in Tanzania from 2007 to 2009, then returned to the US to pursue medical oncology and infectious disease training at UNC-Chapel Hill. After this, he lived with his family in Malawi from 2012 to 2019, when he was the only certified medical oncologist in a country of ~18 million people and treated public sector cancer patients at the national teaching hospital. As an extramural investigator, his NIH-funded research program focused on epidemiologic, clinical, and translational studies of lymphoma and HIV-associated malignancies in sub-Saharan Africa, and he also oversaw a broad, multidisciplinary cancer research portfolio addressing many of the commonest cancers in the region, including cervical, breast, and esophageal cancer. He has spoken widely about global oncology, including at the 2018 Fogarty International Center’s 50th Anniversary Scientific Symposium, in Bethesda, MD. He also served as the Associate Chair for African International Sites for the NCI AIDS Malignancy Consortium.



### **Benjamin Olney Anderson, MD, FACS**

Dr. Anderson is Professor of Surgery and Global Health Medicine at the University of Washington (UW). As surgical director of the UW Breast Health Clinic, Dr. Anderson's cared for patients with breast diseases from 1994-2020. He served as president of the American Society of Breast Disease from 2005–07 and vice chair of the National Comprehensive Cancer Network (NCCN) Breast Panel from 2013-20. He has worked internationally in global cancer control for over two decades. With joint appointments at the Fred Hutchinson Cancer Research Center Division of Public Health Sciences and the UW Department of Global Health, Dr. Anderson chaired the Breast Health Global Initiative, which pioneered the development of "resource-stratified" guidelines in low- and middle-income countries. Dr. Anderson served on the Board of Directors of the Union for International Cancer Control (UICC) from 2012 - 2018. He received the 2011 Partners in Progress Award from the American Society of Clinical Oncology (ASCO), the 2013 Inspiration Award from the National Consortium of Breast Centers, and the 2019 Pioneers of Global Health Award from the Washington Global Health Alliance. In 2020, he joined the World Health Organization (WHO) and now serves as WHO Medical Officer leading the Global Breast Cancer Initiative launched in March 2021.



### **Cary Adams, MBA, PhD (Hon)**

Dr Adams is Chief Executive Officer, Union for International Cancer Control (UICC). Born in London, Dr. Adams has a BSc Honours degree in Economics, Computing and Statistics from the University of Bath, United Kingdom and a master's degree (with distinction) in Business Administration. He is a Harvard Business School Alumnus having attended the school's 2003 Executive General Management programme. In 2009, Dr. Adams made a career change, moving from the management of international businesses in the banking sector to become CEO of UICC based in Geneva. UICC unites and supports the cancer community to reduce the global cancer burden, to promote greater equity, and to ensure that cancer control is a priority in the world health and development agenda. Its rapidly increasing membership base of over 1100 organisations in more than 170 countries features the world's major cancer societies, ministries of health and patient groups and includes influential policy makers, researchers and experts in cancer prevention and control. UICC also boasts more than 50 strategic partners. Dr. Adams and his team focus on global advocacy, convening the cancer community (through World Cancer Day, the World Cancer Congress and the World Cancer Leaders' Summit) and running significant global capacity building projects that address global cancer issues. Dr. Adams also serves as a member of the Board of Directors of the NCD Alliance, a coalition of around 2,000 organisations working on non-communicable diseases, which include cancer, diabetes, heart, respiratory, mental and neurological diseases. He is also an advisor to the City Cancer Challenge Foundation and the McCabe Centre for Law on Cancer. In 2014, he was awarded an Honorary Doctorate in International Relations from the University for Business and International Studies in Geneva and in 2015, an Honorary Doctorate in Health from Bath University in the UK. In May 2015, Dr. Adams was awarded 'CEO of the year' at the International and European Association conference organised by the Associations Network.

**Christopher Booth, MD, FRCPC**

Dr Booth is a Medical Oncologist and Health Services Researcher at Queen's University in Kingston, Ontario, Canada. He is a Professor of Oncology and Public Health Sciences and holds the Canada Research Chair in Population Cancer Care. Dr. Booth is the Director of the Division of Cancer Care and Epidemiology at Queen's Cancer Research Institute. Dr. Booth studied medicine at Queen's University. He did postgraduate training in Internal Medicine and Medical Oncology at the University of Toronto followed by a research fellowship with the NCIC Clinical Trials Group. In his clinical practice he provides care to patients with gastrointestinal cancers. Dr. Booth's research program explores access, quality, and value of cancer care in Canada and globally. In 2016 Dr. Booth spent a sabbatical as a visiting scientist at the Regional Cancer Centre in Trivandrum, India. He is an Advisor (Health Services Research) to the National Cancer Grid of India, an Honorary Consultant at Pallium India, and a member of the WHO Essential Medicine List Cancer Working Group. Dr. Booth has published over 300 peer-reviewed manuscripts and has served as research supervisor for >30 trainees. In 2022 he received the Exceptional Healer Award at Kingston Health Sciences Centre for embodying compassion, respect, and clinical excellence. He was inducted as Fellow of the Canadian Academy of Health Sciences in 2022.

**Ophira Ginsburg, MD, MSc**

Dr. Ginsburg is a medical oncologist and global women's health researcher with nearly 20 years of experience in global cancer prevention and control. In 2022 she joined the U.S. National Institutes of Health, as a Senior Advisor for Clinical Research at the National Cancer Institute's Center for Global Health. She is an alumnus of Queen's University (Kingston), (BSc Hons '89, MD '98), McGill University (MSc Human Genetics, 92), and University of Toronto (Internal Medicine/Medical Oncology, '03, '04). She was an Associate Professor at U of T until 2015-2016 when she joined the World Health Organization (WHO) in Geneva, Switzerland as a Medical Officer. From 2017-2021 she was the Director of the High-Risk Cancer Genetics Program at the Perlmutter Cancer Center, an NCI Designated Comprehensive Cancer Center, and an Associate Professor in the Departments of Population Health and Medicine at NYU Grossman School

of Medicine in New York. Prior to joining the NCI, in 2021 Dr. Ginsburg was appointed as a Senior Visiting Scientist at the International Agency for Research on Cancer (IARC), the WHO's specialized cancer agency. Her research is focused on improving equitable access to breast and cervical cancer prevention and control, using a variety of methods including genetic epidemiology, clinical trials, and implementation research. She has authored >100 peer-reviewed publications and over a dozen commentaries in *The Lancet*, *The Lancet Oncology*, and other *Lancet* journals, *Journal of Clinical Oncology*, *Nature Medicine*, *Nature Cancer*, and *Nature Reviews Clinical Oncology*. She currently co-chairs The Lancet Commission on Women and Cancer.



**Ipshita Prakash, MD, MSc, FRCSC**

Dr Prakash is an Assistant Professor in the Departments of Oncology and Surgery at McGill University. She completed her general surgery residency training at McGill, earned an MSc in healthcare policy and financing at the London School of Economics and London School of Hygiene & Tropical Medicine and completed a fellowship in Breast Surgical Oncology at Duke University in Durham, North Carolina. During her residency, she was part of the Centre for Global Surgery, where she led several studies related to the cost of trauma care in low- and middle-income countries (LMICs) as well as the development of a national surgical plan for Burundi. She eventually melded her research interest in global surgery with her clinical focus and is now an active member of the Global Breast Cancer Initiative, where she is working with other experts in the field to provide an action plan to the World Health Organization for reducing global breast cancer mortality. During her fellowship, Dr. Prakash also developed an expertise in health services research by analysing patterns of breast cancer care in large, contemporary cohorts of breast cancer patients using national cancer databases and by studying the drivers of low value care in breast

cancer patients. The progression of her academic experience has led her to develop an interest in studying financial toxicity in women with breast cancer in Canada. Despite the universal healthcare system in Canada, there is evidence that financial toxicity affects Canadian breast cancer patients, and that it is driven by inequities in social determinants of health. Dr. Prakash hopes to use the lessons learned from the Canadian healthcare systems to help improve access to breast cancer care for women in LMICs.

**Elisabete Weiderpass, MD, MSc, PhD**

In January 2019, Dr Weiderpass took office as elected Director of the International Agency for Research on Cancer (IARC, [www.iarc.fr](http://www.iarc.fr)), the specialized cancer agency of the World Health Organization (WHO), based in Lyon, France. Dr Weiderpass is a Brazilian cancer researcher who is a naturalized Swedish and Finnish citizen. She is an expert in cancer epidemiology and cancer prevention. The Agency welcomes about 350 staff dedicated to cancer research. Its membership and governance is made up of 27 countries (or 'participating States'). Dr Weiderpass previously served as Head of the Department of Research at the Cancer Registry of Norway, and of the Genetic Epidemiology Group at the Folkhälsan Research Center in Finland. She was a Professor of Medical Epidemiology at the Karolinska Institutet in Stockholm, Sweden, and a Professor of Cancer Epidemiology at the Arctic University of Norway. She held visiting professorship positions in cancer epidemiology in Brazil, China, the Islamic Republic of Iran, and Kuwait and is an honorary Adjunct

Professor at the Yale School of Public Health in the USA. Dr Weiderpass has authored over 900 scientific publications in peer-reviewed international journals. As IARC Director, she oversees one of the most prominent research, educational, and service programs to advance cancer prevention and control worldwide. The IARC has served as the training ground for generations of talented cancer researchers since its inauguration in 1965.



**Danielle Rodin, MD, MPH, FRCPC**

Dr Rodin is a radiation oncologist at Princess Margaret Cancer Centre (PM) and an Assistant Professor in the Department of Radiation Oncology at University of Toronto (UTDRO). She is Director of the Global Cancer Program at PM, Director of Equity, Diversity, and Professionalism at UTDRO, and an elected member of the Board of Directors for the Union for International Cancer Control in Geneva. Her clinical interests are in breast cancer and hematologic malignancies and she is a health services researcher, with a focus on global access to cancer treatment and how patient, physician, and health system policies impact the delivery of high-quality and cost-effective care. Dr. Rodin received her B.A. (Hons.) from McGill University, her medical degree from the University of Toronto, and her Master of Public Health from Harvard University. She was the 2017-18 Harkness Fellow in Health Care Policy and Practice in the Department of Health Policy and Management at the Harvard T. H. Chan School of Public Health, where she focused on low-value care across international health

systems. She was a member of the two *Lancet Oncology* commissions on radiotherapy and on surgical oncology, and her work has informed the 2020 World Health Assembly draft resolution on cervical cancer. She has developed partnerships in education, clinical care, and research with cancer centres in India, Brazil, and Jordan, and has been a longstanding consultant to the International Atomic Energy Agency on addressing disparities in access to radiotherapy.

**Meredith Giuliani MBBS, MEd, PhD, FRCPC**

Dr Giuliani is an Associate Professor in the Department of Radiation Oncology at the University of Toronto and the Director of Education at Princess Margaret Cancer Centre. Dr Giuliani received her MBBS qualification from the University of London, England and she then completed her residency training in radiation oncology at the University of Toronto. She received her Master's of Education from the Ontario Institute of Sciences in Education at the University of Toronto and her PhD from the School of Health Professions Education at Maastricht University. Her PhD focused on globalization and the influence of neocolonialism on oncology curricula. Her education research activity focuses on globalization, the influence of education on health systems and the intersection of education and health disparities. Her clinical interests are in thoracic cancers.

## Course Coordinators:



### **Eduardo L. Franco, O.C., MPH, DrPH, PhD (Hon.), FRSC, FCAHS**

Dr Franco is James McGill Professor of Oncology and Epidemiology; Chairman, Department of Oncology; and Director, Division of Cancer Epidemiology, McGill University. He is trained in public health microbiology at University of North Carolina and at the US Centers for Disease Control, and as a cancer epidemiologist at the National Institutes of Health, International Agency for Research on Cancer, and Louisiana State University. His research has focused on epidemiology and prevention of gynecologic, anogenital, oral, prostate, and childhood cancers. He is mostly known for his contributions to our understanding of human papillomavirus infection as the cause of cervical cancer and to preventing this disease via vaccination and improved screening strategies. He mentored 135 graduate students and postdoctoral fellows nationally and internationally. In addition to his McGill teaching, he has

taught short courses on cancer epidemiology and scientific publishing throughout the world. He is Editor-in-Chief of the *Journal of the National Cancer Institute* (as of January 1, 2023), and former Editor-in-Chief of *Preventive Medicine* (2013-2022). He is Officer of the Order of Canada and Fellow of the Royal Society of Canada and of the Canadian Academy of Health Sciences. He received the Canadian Cancer Research Alliance's Distinguished Service to Cancer Research Award; Lifetime Achievement Awards from the American Society for Colposcopy and Cervical Pathology and from the International Papillomavirus Society; the Women in U.S. Government's Leadership Award; the Canadian Cancer Society's Warwick Prize; the Geoffrey Howe Outstanding Contribution Award from the Canadian Society for Epidemiology and Biostatistics; University of British Columbia's Chew Wei Memorial Prize in Cancer Research; and the McLaughlin-Gallie Award from the Royal College of Physicians of Canada. He is Foreign Member of the Brazilian Academy of Sciences.



### **Argerie Tsimicalis, RN, MSc, PhD**

Dr Tsimicalis is the Director of McGill's Global Oncology Program, a partnership between the Department of Oncology and School of Population and Global Health. She is an Associate Professor in the Ingram School of Nursing and an Associate Member in the Department of Oncology, Faculty of Medicine, McGill University. Her clinical appointments include two Nurse Scientist positions at the Shriners Hospitals for Children-Canada and Montreal University Health Centre (MUHC). She is internationally recognized for her expertise in assessing the costs associated with a childhood illness in the family. In partnership with key stakeholders and patient organizations, Argerie seeks to help render these potentially catastrophic costs visible and to create programs, resources, and policies to help lessen their costs. Dr. Tsimicalis has collaborated with a network of scientists, clinicians, decision makers, students, patients, and philanthropists from Australia, Brazil, Canada, El Salvador, Norway, India, Indonesia, Guatemala, the Netherlands, the United Kingdom, and the

United States. Her students come from a wide range of backgrounds including nursing, medicine, music, aging, psychology, education, biochemistry, epidemiology, business administration, and informatics. She offers transdisciplinary training opportunities to undergraduate and graduate students through the McGill Global Health Programs.